<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323294</url>
  </required_header>
  <id_info>
    <org_study_id>BMPP</org_study_id>
    <secondary_id>206164</secondary_id>
    <secondary_id>1P20GM109096-01A1</secondary_id>
    <nct_id>NCT03323294</nct_id>
  </id_info>
  <brief_title>Bioenergetics and Metabolism in Pediatric Populations</brief_title>
  <official_title>Bioenergetics and Metabolism in Pediatric Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arkansas Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arkansas Children's Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to learn more about obesity, the development of insulin resistance,
      and Type 2 Diabetes in children. The investigators will do this through collecting
      information about children's health and conducting experiments on a variety of samples.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Altered circulating blood cell bioenergetics</measure>
    <time_frame>After completion of all study visits, approximately 2 years.</time_frame>
    <description>The investigators hypothesize that when compared to normal weight or obese insulin sensitive children, obese insulin resistant children will exhibit altered circulating blood cell bioenergetics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidized plasma redox state</measure>
    <time_frame>After completion of all study visits, approximately 2 years.</time_frame>
    <description>The investigators hypothesize that when compared to normal weight or obese insulin sensitive children, obese insulin resistant children will exhibit a more oxidized plasma redox state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alterations in resting energy expenditure</measure>
    <time_frame>After completion of all study visits, approximately 2 years.</time_frame>
    <description>The investigators hypothesize that when compared to normal weight or obese insulin sensitive children, obese insulin resistant children will be associated with alterations of decreased resting energy expenditure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alterations in fatty acid oxidation</measure>
    <time_frame>After completion of all study visits, approximately 2 years.</time_frame>
    <description>We hypothesize that when compared to normal weight or obese insulin sensitive children, obese insulin resistant children will be associated with alterations of impaired fatty acid oxidation (FAO).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Poor oxidative capacity</measure>
    <time_frame>After completion of all study visits, approximately 2 years.</time_frame>
    <description>The investigators hypothesize that poor oxidative capacity over time may distinguish between metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) phenotypes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predicting Type 2 Diabetes development</measure>
    <time_frame>After completion of all study visits, approximately 2 years.</time_frame>
    <description>The investigators hypothesize that poor oxidative capacity over time may be predictive of Type 2 Diabetes development.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioenergetics in Type 2 Diabetes with metformin</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators hypothesize that the change in bioenergetics will be improved in obese Type 2 Diabetes children at 6 months of metformin therapy that will be prescribed as part of their clinical care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resting Energy Expenditure in Type 2 Diabetes with metformin</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators hypothesize that the change in resting energy expenditure will be improved in obese Type 2 Diabetes children at 6 months of metformin therapy that will be prescribed as part of their clinical care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatty Acid Oxidation in Type 2 Diabetes with metformin</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators hypothesize that the change in fatty acid oxidation will be improved in obese Type 2 Diabetes children at 6 months of metformin therapy that will be prescribed as part of their clinical care.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Healthy Lean</arm_group_label>
    <description>Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and &lt;85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Obese</arm_group_label>
    <description>Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Insulin Resistant</arm_group_label>
    <description>Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 Diabetes or Insulin Resistant with Metformin</arm_group_label>
    <description>Obese individuals with Type 2 Diabetes or insulin resistance (n=20) and who are prescribed metformin as part of their clinical care will be asked to complete an additional study visit to occur at 6 months (± 2 weeks) after beginning metformin therapy.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, stool, spit, and cheek cell samples may be retained. The blood sample will be
      used for bioenergetics and analyte analysis. The sample may be used for future research
      studies on pediatric nutrition. Urine samples will be collected to measure fat oxidation. The
      saliva, cheek swab, and stool sample will be used for future research studies on pediatric
      nutrition.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study investigators, research staff, or any qualified personnel will conduct recruitment of
        study participants using IRB approved advertisement. 175 pre-pubertal children ages 5-9
        years old or children diagnosed with type 2 diabetes or insulin resistance ages 5-17 years
        old who are prescribed Metformin therapy will be recruited and may enroll for this study
        with the goal that 130 subjects stratified across the study groups will complete the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 5-9 years and Tanner stage as reported by parent no greater than stage 1 OR Age 5
             years - 17 years 5 months, diagnosed with type 2 diabetes mellitus or insulin
             resistance and prescribed Metformin (not yet taking)

          -  Either healthy lean (BMI≥ 5th percentile and &lt;85th percentile for age/sex) or obese
             (BMI ≥ 95th percentile for age/sex)

          -  For those with BMI≥ 95th percentile for age/sex, parental verbal confirmation will be
             obtained that the child had a history of BMI≥ 95th percentile for age/sex for at least
             six months prior to study enrollment

        Exclusion criteria:

          -  Genetic or physical conditions impacting mobility over past year as determined by the
             Principal Investigator (PI)

          -  Having known chronic illnesses/disorders that may independently affect study outcome
             measures: type 1 diabetes mellitus, neurologic (e.g. epilepsy), developmental
             (developmental delay, autism spectrum disorder), endocrine (thyroid, Cushing's),
             hepatic, autoimmune, cardiac and renal disorders. Also, chronic lung disorders except
             well controlled asthma that does not require permanent use of inhaled/oral steroids

          -  Taking any of the following medications that can affect study outcome: antipsychotics,
             thyroid hormone replacement therapy, inhaled/oral steroids, insulin, anabolic drugs
             (growth hormone replacement therapy and oxandrolone) and stimulants

          -  Taking metformin prescribed as part of their clinical care at the time of enrollment
             (may begin metformin therapy prescribed as part of their clinical care while enrolled
             in the study)

          -  BMI&lt;5th percentile for age/sex (classified as underweight based on Centers for Disease
             Control and Prevention growth charts)

          -  Subjects determined ineligible by the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon Rose, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Arkansas Children's Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugenia Carvalho, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arkansas Children's Nutrition Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leanna Delhey, MPH</last_name>
    <phone>501-364-4519</phone>
    <email>delheylm@archildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanna Delhey, BS, MPH</last_name>
      <phone>501-364-4519</phone>
      <email>delheylm@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Eugenia Carvalho, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Rose, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabet Borsheim, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Oden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shipra Bansal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emir Tas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stepan Melnyk, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Weber, PhD, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000 Sep;23(9):1278-83.</citation>
    <PMID>10977060</PMID>
  </reference>
  <reference>
    <citation>Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab. 2007 Nov;9(6):813-39. Review.</citation>
    <PMID>17924865</PMID>
  </reference>
  <reference>
    <citation>Civitarese AE, Ravussin E. Mitochondrial energetics and insulin resistance. Endocrinology. 2008 Mar;149(3):950-4. doi: 10.1210/en.2007-1444. Epub 2008 Jan 17. Review.</citation>
    <PMID>18202132</PMID>
  </reference>
  <reference>
    <citation>Hesselink MK, Schrauwen-Hinderling V, Schrauwen P. Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus. Nat Rev Endocrinol. 2016 Nov;12(11):633-645. doi: 10.1038/nrendo.2016.104. Epub 2016 Jul 22. Review.</citation>
    <PMID>27448057</PMID>
  </reference>
  <reference>
    <citation>Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev. 2010 Jun;31(3):364-95. doi: 10.1210/er.2009-0027. Epub 2010 Feb 15. Review.</citation>
    <PMID>20156986</PMID>
  </reference>
  <reference>
    <citation>Codoñer-Franch P, Pons-Morales S, Boix-García L, Valls-Bellés V. Oxidant/antioxidant status in obese children compared to pediatric patients with type 1 diabetes mellitus. Pediatr Diabetes. 2010 Jun;11(4):251-7. doi: 10.1111/j.1399-5448.2009.00565.x. Epub 2009 Sep 16.</citation>
    <PMID>19671090</PMID>
  </reference>
  <reference>
    <citation>Faienza MF, Francavilla R, Goffredo R, Ventura A, Marzano F, Panzarino G, Marinelli G, Cavallo L, Di Bitonto G. Oxidative stress in obesity and metabolic syndrome in children and adolescents. Horm Res Paediatr. 2012;78(3):158-64. doi: 10.1159/000342642. Epub 2012 Oct 10.</citation>
    <PMID>23052543</PMID>
  </reference>
  <reference>
    <citation>Marin MT, Dasari PS, Tryggestad JB, Aston CE, Teague AM, Short KR. Oxidized HDL and LDL in adolescents with type 2 diabetes compared to normal weight and obese peers. J Diabetes Complications. 2015 Jul;29(5):679-85. doi: 10.1016/j.jdiacomp.2015.03.015. Epub 2015 Apr 6.</citation>
    <PMID>25881918</PMID>
  </reference>
  <reference>
    <citation>Matusik P, Prokopowicz Z, Norek B, Olszanecka-Glinianowicz M, Chudek J, Malecka-Tendera E. Oxidative/Antioxidative status in obese and sport trained children: a comparative study. Biomed Res Int. 2015;2015:315747. doi: 10.1155/2015/315747. Epub 2015 Mar 31.</citation>
    <PMID>25918709</PMID>
  </reference>
  <reference>
    <citation>Vehapoglu A, Turkmen S, Goknar N, Özer ÖF. Reduced antioxidant capacity and increased subclinical inflammation markers in prepubescent obese children and their relationship with nutritional markers and metabolic parameters. Redox Rep. 2016 Nov;21(6):271-80. doi: 10.1080/13510002.2015.1133035. Epub 2016 Feb 19.</citation>
    <PMID>26865084</PMID>
  </reference>
  <reference>
    <citation>Albuali WH. Evaluation of oxidant-antioxidant status in overweight and morbidly obese Saudi children. World J Clin Pediatr. 2014 Feb 8;3(1):6-13. doi: 10.5409/wjcp.v3.i1.6. eCollection 2014 Feb 8.</citation>
    <PMID>25254179</PMID>
  </reference>
  <reference>
    <citation>Codoñer-Franch P, Boix-García L, Simó-Jordá R, Del Castillo-Villaescusa C, Maset-Maldonado J, Valls-Bellés V. Is obesity associated with oxidative stress in children? Int J Pediatr Obes. 2010;5(1):56-63. doi: 10.3109/17477160903055945.</citation>
    <PMID>19565402</PMID>
  </reference>
  <reference>
    <citation>Paltoglou G, Fatouros IG, Valsamakis G, Schoina M, Avloniti A, Chatzinikolaou A, Kambas A, Draganidis D, Mantzou A, Papagianni M, Kanaka-Gantenbein C, Chrousos GP, Mastorakos G. Antioxidation improves in puberty in normal weight and obese boys, in positive association with exercise-stimulated growth hormone secretion. Pediatr Res. 2015 Aug;78(2):158-64. doi: 10.1038/pr.2015.85. Epub 2015 May 4.</citation>
    <PMID>25938733</PMID>
  </reference>
  <reference>
    <citation>Santillán LD, Moyano M, Frau M, Flores O, Siewert S, Zirulnick F, Ramirez DC, Giménez MS. Reduced blood nrf-2 mRNA in local overweight boys at risk of metabolic complications: a study in San Luis City, San Luis, Argentina. Metab Syndr Relat Disord. 2013 Oct;11(5):359-65. doi: 10.1089/met.2012.0155. Epub 2013 Jun 28.</citation>
    <PMID>23809001</PMID>
  </reference>
  <reference>
    <citation>Simoneau JA, Colberg SR, Thaete FL, Kelley DE. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J. 1995 Feb;9(2):273-8.</citation>
    <PMID>7781930</PMID>
  </reference>
  <reference>
    <citation>Simoneau JA, Bouchard C. Skeletal muscle metabolism and body fat content in men and women. Obes Res. 1995 Jan;3(1):23-9.</citation>
    <PMID>7712356</PMID>
  </reference>
  <reference>
    <citation>Simoneau JA, Kelley DE. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol (1985). 1997 Jul;83(1):166-71.</citation>
    <PMID>9216960</PMID>
  </reference>
  <reference>
    <citation>Simoneau JA, Kelley DE, Neverova M, Warden CH. Overexpression of muscle uncoupling protein 2 content in human obesity associates with reduced skeletal muscle lipid utilization. FASEB J. 1998 Dec;12(15):1739-45.</citation>
    <PMID>9837864</PMID>
  </reference>
  <reference>
    <citation>Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999 Dec;277(6 Pt 1):E1130-41.</citation>
    <PMID>10600804</PMID>
  </reference>
  <reference>
    <citation>Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005 Jan;54(1):8-14.</citation>
    <PMID>15616005</PMID>
  </reference>
  <reference>
    <citation>Ritov VB, Menshikova EV, Azuma K, Wood R, Toledo FG, Goodpaster BH, Ruderman NB, Kelley DE. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E49-58. doi: 10.1152/ajpendo.00317.2009. Epub 2009 Nov 3.</citation>
    <PMID>19887598</PMID>
  </reference>
  <reference>
    <citation>Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002 Oct;51(10):2944-50.</citation>
    <PMID>12351431</PMID>
  </reference>
  <reference>
    <citation>Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8466-71. Epub 2003 Jun 27.</citation>
    <PMID>12832613</PMID>
  </reference>
  <reference>
    <citation>Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes. 2002 Jun;51(6):1913-20.</citation>
    <PMID>12031981</PMID>
  </reference>
  <reference>
    <citation>Ten S, Bhangoo A, Ramchandani N, Mueller C, Vogiatzi M, New M, Lesser M, Maclaren N. Resting energy expenditure in insulin resistance falls with decompensation of insulin secretion in obese children. J Pediatr Endocrinol Metab. 2008 Apr;21(4):359-67.</citation>
    <PMID>18556967</PMID>
  </reference>
  <reference>
    <citation>De Pergola G, Pannacciulli N, Minenna A, Martina RA, Cannito F, Giorgino R. Fuel metabolism in adult individuals with a wide range of body mass index: effect of a family history of type 2 diabetes. Diabetes Nutr Metab. 2003 Feb;16(1):41-7.</citation>
    <PMID>12848304</PMID>
  </reference>
  <reference>
    <citation>Chacko BK, Kramer PA, Ravi S, Benavides GA, Mitchell T, Dranka BP, Ferrick D, Singal AK, Ballinger SW, Bailey SM, Hardy RW, Zhang J, Zhi D, Darley-Usmar VM. The Bioenergetic Health Index: a new concept in mitochondrial translational research. Clin Sci (Lond). 2014 Sep;127(6):367-73. doi: 10.1042/CS20140101. Review.</citation>
    <PMID>24895057</PMID>
  </reference>
  <reference>
    <citation>Kramer PA, Chacko BK, Ravi S, Johnson MS, Mitchell T, Darley-Usmar VM. Bioenergetics and the oxidative burst: protocols for the isolation and evaluation of human leukocytes and platelets. J Vis Exp. 2014 Mar 27;(85). doi: 10.3791/51301.</citation>
    <PMID>24747339</PMID>
  </reference>
  <reference>
    <citation>Tyrrell DJ, Bharadwaj MS, Van Horn CG, Marsh AP, Nicklas BJ, Molina AJ. Blood-cell bioenergetics are associated with physical function and inflammation in overweight/obese older adults. Exp Gerontol. 2015 Oct;70:84-91. doi: 10.1016/j.exger.2015.07.015. Epub 2015 Jul 29.</citation>
    <PMID>26226578</PMID>
  </reference>
  <reference>
    <citation>Nijhawan S, Richards W, O'Hea MF, Audia JP, Alvarez DF. Bariatric surgery rapidly improves mitochondrial respiration in morbidly obese patients. Surg Endosc. 2013 Dec;27(12):4569-73. doi: 10.1007/s00464-013-3125-y. Epub 2013 Aug 24.</citation>
    <PMID>23982645</PMID>
  </reference>
  <reference>
    <citation>Tyrrell DJ, Bharadwaj MS, Jorgensen MJ, Register TC, Molina AJ. Blood cell respirometry is associated with skeletal and cardiac muscle bioenergetics: Implications for a minimally invasive biomarker of mitochondrial health. Redox Biol. 2016 Dec;10:65-77. doi: 10.1016/j.redox.2016.09.009. Epub 2016 Sep 21.</citation>
    <PMID>27693859</PMID>
  </reference>
  <reference>
    <citation>Bervoets L, Massa G. Classification and clinical characterization of metabolically &quot;healthy&quot; obese children and adolescents. J Pediatr Endocrinol Metab. 2016 May 1;29(5):553-60. doi: 10.1515/jpem-2015-0395.</citation>
    <PMID>26910741</PMID>
  </reference>
  <reference>
    <citation>Muñoz-Garach A, Cornejo-Pareja I, Tinahones FJ. Does Metabolically Healthy Obesity Exist? Nutrients. 2016 Jun 1;8(6). pii: E320. doi: 10.3390/nu8060320. Review.</citation>
    <PMID>27258304</PMID>
  </reference>
  <reference>
    <citation>Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Melnyk S, James SJ. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl Psychiatry. 2014 Apr 1;4:e377. doi: 10.1038/tp.2014.15. Erratum in: Transl Psychiatry. 2015;5:e526.</citation>
    <PMID>24690598</PMID>
  </reference>
  <reference>
    <citation>Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Pavliv O, Melnyk S, James SJ. Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort. PLoS One. 2014 Jan 8;9(1):e85436. doi: 10.1371/journal.pone.0085436. eCollection 2014.</citation>
    <PMID>24416410</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Pediatric Health</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Metformin Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The information collected at the study visit, saliva, cheek swabs, blood, urine, and stool samples may be stored indefinitely and may be used for future research studies on pediatric nutrition. Prior to the information collected at the study visit and samples being used for future research studies, the PI will assess the ethics and scientific merit of the proposed research with the samples, and proposed future research will be reviewed by the IRB as may be required. The samples and health information collected for the study visit may be shared with researchers at the University of Arkansas for Medical Sciences, Arkansas Children's Hospital, or Arkansas Children's Research Institute. The samples may be shared with an outside group. The samples will only have a study number and study acronym to maintain confidentiality.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

